CoChat

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Asperosaponin VI ameliorates the CMS-induced depressive-like behaviors by inducing a neuroprotective microglial phenotype in hippocampus via PPAR-γ pathway

Open access
Jiang, Xue, Yi, Saini, Liu, Qin, Su, Dapeng, Li, Liangyuan, Xiao, Chenghong, Zhang, Jinqiang · 2022 · Journal of Neuroinflammation

Abstract

Background: The natural compound asperosaponin VI has shown potential as an antidepressant, but how it works is unclear. Here, we explored its effects on mice exposed to chronic mild stress (CMS) and the underlying molecular pathways. Methods: Mice were exposed to CMS for 3 weeks followed by asperosaponin VI (40 mg/kg) or imipramine (20 mg/kg) for another 3 weeks. Depression-like behaviors were assessed in the forced swimming test (FST), sucrose preference test (SPT), tail suspension test (TST). Microglial phenotypes were evaluated using immunofluorescence staining, real-time quantitative PCR and enzyme-linked immunosorbent assays in hippocampus of mice. In some experiments, stressed animals were treated with the PPAR-γ antagonist GW9662 to examine its involvement in the effects of asperosaponin VI. Blockade of PPAR-γ in asperosaponin VI-treated primary microglia in the presence of lipopolysaccharide (LPS) was executed synchronously. The nuclear transfer of PPAR-γ in microglia was detected by immunofluorescence staining in vitro and in vivo. A co-cultured model of neuron and microglia was used for evaluating the regulation of ASA VI on the microglia–neuron crosstalk molecules. Results: Asperosaponin VI ameliorated depression-like behaviors of CMS mice based on SPT, TST and FST, and this was associated with a switch of hippocampal microglia from a pro-inflammatory (iNOS+-Iba1+) to neuroprotective (Arg-1+-Iba1+) phenotype. CMS reduced the expression levels of PPAR-γ and phosphorylated PPAR-γ in hippocampus, which asperosaponin VI partially reversed. GW9662 treatment prevented the nuclear transfer of PPAR-γ in asperosaponin VI-treated microglia and inhibited the induction of Arg-1+ microglia. Blockade of PPAR-γ signaling also abolished the ability of asperosaponin VI to suppress pro-inflammatory cytokines while elevating anti-inflammatory cytokines in the hippocampus of CMS mice. The asperosaponin VI also promoted interactions between hippocampal microglia and neurons by enhancing CX3CL1/CX3CR1 and CD200/CD200R, and preserved synaptic function based on PSD95, CamKII β and GluA levels, but not in the presence of GW9662. Blockade of PPAR-γ signaling also abolished the antidepressant effects of asperosaponin VI in the SPT, TST and FST. Conclusion: CMS in mice induces a pro-inflammatory microglial phenotype that causes reduced crosstalk between microglia and neuron, inflammation and synaptic dysfunction in the hippocampus, ultimately leading to depression-like behaviors. Asperosaponin VI may ameliorate the effects of CMS by inducing microglia to adopt a PPAR-γ-dependent neuroprotective phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-022-02478-y

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Asperosaponin VI ameliorates CMS-induced depression-like behaviors. A Timeline of the experimental process. B Sucrose preference during 6 weeks in Ctrl mice and mice subjected to CMS, followed by treatment with ASA VI or IMI. *p < 0.05, **p < 0.01 vs Ctrl group, #p < 0.05, ##p < 0.01, ###p < 0.001 vs CMS group. C Sucrose preference of individual mice before treatment (3-week) or after treatment (6-week) with ASA VI or IMI. D Latency and time spent immobile in the TST. E Latency and time spent immobile in the FST. F Latency to feed in the NSFT. G Distance travelled in the OFT. H Body weight of Ctrl or CMS mice before treatment (3-week) or after treatment (6-week) with ASA VI or IMI. Data for individual animals are displayed (mean ± SEM, n = 8–12 per group). *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA with Tukey's multiple-comparisons test). ASA VI, asperosaponin VI; CMS, chronic mild stress; Ctrl, the control; IMI, imipramine; TST, tail suspension test; FST, forced swimming test; NSFT, novelty-suppressed feeding test; OFT, open field test
Fig. 1 Asperosaponin VI ameliorates CMS-induced depression-like behaviors. A Timeline of the experimental process. B Sucrose preference during 6 weeks in Ctrl mice and mice subjected to CMS, followed by treatment with ASA VI or IMI. *p < 0.05, **p < 0.01 vs Ctrl group, #p < 0.05, ##p < 0.01, ###p < 0.001 vs CMS group. C Sucrose preference of individual mice before treatment (3-week) or after treatment (6-week) with ASA VI or IMI. D Latency and time spent immobile in the TST. E Latency and time spent immobile in the FST. F Latency to feed in the NSFT. G Distance travelled in the OFT. H Body weight of Ctrl or CMS mice before treatment (3-week) or after treatment (6-week) with ASA VI or IMI. Data for individual animals are displayed (mean ± SEM, n = 8–12 per group). *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA with Tukey's multiple-comparisons test). ASA VI, asperosaponin VI; CMS, chronic mild stress; Ctrl, the control; IMI, imipramine; TST, tail suspension test; FST, forced swimming test; NSFT, novelty-suppressed feeding test; OFT, open field testCC BY · PubMed Central
Fig. 2 Effects of asperosaponin VI on the morphology of microglia in hippocampus of CMS mice. A Representative micrographs of microglia in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. Microglia were stained with Iba1 (red) by immunocytochemistry, and nuclei were stained with DAPI (blue). B–E Quantification of the area and number of Iba1+ cells, number and length of microglial branches in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. Results of each group were obtained from 5 mice, and 5–6 micrographs (40 ×) containing hippocampus were collected from each sample. All Iba1+ cells in each micrograph were measured. Each dot in the bar graph represents the average of all Iba1+ cells analyzed for each mouse. F and G Levels of mRNA encoding Iba1 and CD11b in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI (n = 4 animals). Data for individual animals are displayed (mean ± SEM), *p < 0.05, **p < 0.01 (two-way ANOVA with Tukey’s multiple-comparisons test)
Fig. 2 Effects of asperosaponin VI on the morphology of microglia in hippocampus of CMS mice. A Representative micrographs of microglia in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. Microglia were stained with Iba1 (red) by immunocytochemistry, and nuclei were stained with DAPI (blue). B–E Quantification of the area and number of Iba1+ cells, number and length of microglial branches in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. Results of each group were obtained from 5 mice, and 5–6 micrographs (40 ×) containing hippocampus were collected from each sample. All Iba1+ cells in each micrograph were measured. Each dot in the bar graph represents the average of all Iba1+ cells analyzed for each mouse. F and G Levels of mRNA encoding Iba1 and CD11b in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI (n = 4 animals). Data for individual animals are displayed (mean ± SEM), *p < 0.05, **p < 0.01 (two-way ANOVA with Tukey’s multiple-comparisons test)CC BY · PubMed Central
Fig. 3 Asperosaponin VI switches activated microglia from a pro-inflammatory to anti-inflammatory phenotype in hippocampus of CMS mice. A Levels of mRNAs encoding Arg-1 and iNOS in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. B Ratio of the levels of mRNAs encoding Arg-1 to iNOS in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. C Fluorescence micrographs of anti-inflammatory microglia (Arg-1+-Iba1+ cells) in hippocampus of CMS mice after treatment with ASA VI. Anti-inflammatory marker was stained with an antibody against Arg-1 (green); microglia, with an antibody against Iba1 (red); and nuclei, with DAPI (blue). The cells positive for Arg-1 and Iba1 were considered anti-inflammatory microglia. Histogram is quantification of the percentage of Arg-1+-Iba1+ cells. Scale bar, 10 μm. D Fluorescence micrographs of pro-inflammatory microglia (iNOS+-Iba1+ cells) in hippocampus of CMS mice. Pro-inflammatory cytokines were stained with an antibody against iNOS (green). The cells positive for iNOS and Iba1 were considered pro-inflammatory microglia. Histogram is the quantification of the percentage of iNOS+-Iba1+ cells. Scale bar, 10 μm. E Ratio of Arg-1+ microglia to iNOS+ microglia in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. F Schematic illustrating how ASA VI switches activated microglia from a pro-inflammatory to anti-inflammatory phenotype in hippocampus of CMS mice. G Correlation of the ratio of Arg-1+ microglia to iNOS+ microglia in hippocampus or cortex of each group mice with sucrose preference and latency and immobility time in the FST. H Levels of mRNAs encoding the pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and the anti-inflammatory cytokines (IL-10 and TGF-β) and brain-derived neurotrophic factor (BDNF) in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. I Levels of IL-1β, IL-10 and BDNF in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. Data for individual animals are displayed (mean ± SEM, n = 3–5), A, C–E and I *p < 0.05, **p < 0.01, ***p < 0.001. B and H *p < 0.05, *p < 0.01, ***p < 0.001 vs. Ctrl group, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. CMS group (two-way ANOVA with Tukey's multiple-comparisons test)
Fig. 3 Asperosaponin VI switches activated microglia from a pro-inflammatory to anti-inflammatory phenotype in hippocampus of CMS mice. A Levels of mRNAs encoding Arg-1 and iNOS in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. B Ratio of the levels of mRNAs encoding Arg-1 to iNOS in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. C Fluorescence micrographs of anti-inflammatory microglia (Arg-1+-Iba1+ cells) in hippocampus of CMS mice after treatment with ASA VI. Anti-inflammatory marker was stained with an antibody against Arg-1 (green); microglia, with an antibody against Iba1 (red); and nuclei, with DAPI (blue). The cells positive for Arg-1 and Iba1 were considered anti-inflammatory microglia. Histogram is quantification of the percentage of Arg-1+-Iba1+ cells. Scale bar, 10 μm. D Fluorescence micrographs of pro-inflammatory microglia (iNOS+-Iba1+ cells) in hippocampus of CMS mice. Pro-inflammatory cytokines were stained with an antibody against iNOS (green). The cells positive for iNOS and Iba1 were considered pro-inflammatory microglia. Histogram is the quantification of the percentage of iNOS+-Iba1+ cells. Scale bar, 10 μm. E Ratio of Arg-1+ microglia to iNOS+ microglia in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. F Schematic illustrating how ASA VI switches activated microglia from a pro-inflammatory to anti-inflammatory phenotype in hippocampus of CMS mice. G Correlation of the ratio of Arg-1+ microglia to iNOS+ microglia in hippocampus or cortex of each group mice with sucrose preference and latency and immobility time in the FST. H Levels of mRNAs encoding the pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and the anti-inflammatory cytokines (IL-10 and TGF-β) and brain-derived neurotrophic factor (BDNF) in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. I Levels of IL-1β, IL-10 and BDNF in hippocampus and cortex of Ctrl or CMS mice after treatment with saline or ASA VI. Data for individual animals are displayed (mean ± SEM, n = 3–5), A, C–E and I *p < 0.05, **p < 0.01, ***p < 0.001. B and H *p < 0.05, *p < 0.01, ***p < 0.001 vs. Ctrl group, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. CMS group (two-way ANOVA with Tukey's multiple-comparisons test)CC BY · PubMed Central
Fig. 4 Asperosaponin VI activates the PPAR-γ in hippocampal microglia of CMS mice and in primary microglia. A Levels of p-PPAR-γ, PPAR-γ 1 and PPAR-γ 2 in hippocampus of Ctrl or CMS mice after treatment with saline or ASA VI. Levels of PPAR-γ-1 and PPAR-γ-2 were normalized to those of β-actin. Levels of phosphorylated PPAR-γ were normalized to those of PPAR-γ-1 and PPAR-γ-2 (n = 3, each sample in triplicate). B Fluorescence micrographs showing PPAR-γ expression in microglia (as indicated by the white arrow) of hippocampus in CMS mice after treatment with ASA VI. PPAR-γ was stained with antibody (green), microglia were stained with an anti-Iba1 antibody (red), and nuclei were stained with DAPI (blue). The yellow arrow indicates the high-resolution cells inserted in the upper right. The blue arrow indicates that the nuclear transfer of PPAR-γ is in the hippocampal microglia. Scale bar, 20 μm. C Fluorescence micrographs showing PPAR-γ expression in Arg-1+ cells (as indicated by the white arrow) of hippocampus in CMS mice after treatment with ASA VI. Scale bar, 10 μm. D Schematic illustrating ASA VI switches activated microglia from a pro-inflammatory (iNOS+) to anti-inflammatory (Arg-1+) phenotype via the PPAR-γ activation in hippocampus of CMS mice. E Experimental scheme to monitor the effect of GW9662 on PPAR-γ in Ctrl, lipopolysaccharide (LPS), LPS + ASA VI and LPS + ASA VI + GW9662 in primary microglia. F Fluorescence micrographs showing nuclear translocation of PPAR-γ in Ctrl, LPS, LPS + ASA VI and LPS + ASA VI + GW9662 microglia. PPAR-γ was stained with PPAR-γ antibody (green), Arg-1 in microglia were stained with an anti-Arg-1 antibody (red), and nuclei were stained with DAPI (blue). Scale bar, 10 μm. G Effects of GW9662 treatment on levels of p-PPAR-γ in Ctrl, LPS, LPS + ASA VI and LPS + ASA VI + GW9662 microglia (n = 3, each sample in triplicate). H Levels of mRNAs encoding the pro-inflammatory cytokines (TNF-α, iNOS, IL-1β, and IL-6) and the anti-inflammatory cytokines (Arg-1, IL-10 and TGF-β) and BDNF in Ctrl, LPS, LPS + ASA VI and LPS + ASA VI + GW9662 microglia. Data are displayed with mean ± SEM (n = 3–5), A *p < 0.05, ***p < 0.001 (two-way ANOVA with Tukey’s multiple-comparisons test). G and H *p < 0.05, *p < 0.01, ***p < 0.001 vs. Ctrl group, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. LPS group, &p < 0.05, &&&p < 0.001 vs. LPS + ASA VI group (one-way ANOVA with Tukey’s multiple-comparisons test)
Fig. 4 Asperosaponin VI activates the PPAR-γ in hippocampal microglia of CMS mice and in primary microglia. A Levels of p-PPAR-γ, PPAR-γ 1 and PPAR-γ 2 in hippocampus of Ctrl or CMS mice after treatment with saline or ASA VI. Levels of PPAR-γ-1 and PPAR-γ-2 were normalized to those of β-actin. Levels of phosphorylated PPAR-γ were normalized to those of PPAR-γ-1 and PPAR-γ-2 (n = 3, each sample in triplicate). B Fluorescence micrographs showing PPAR-γ expression in microglia (as indicated by the white arrow) of hippocampus in CMS mice after treatment with ASA VI. PPAR-γ was stained with antibody (green), microglia were stained with an anti-Iba1 antibody (red), and nuclei were stained with DAPI (blue). The yellow arrow indicates the high-resolution cells inserted in the upper right. The blue arrow indicates that the nuclear transfer of PPAR-γ is in the hippocampal microglia. Scale bar, 20 μm. C Fluorescence micrographs showing PPAR-γ expression in Arg-1+ cells (as indicated by the white arrow) of hippocampus in CMS mice after treatment with ASA VI. Scale bar, 10 μm. D Schematic illustrating ASA VI switches activated microglia from a pro-inflammatory (iNOS+) to anti-inflammatory (Arg-1+) phenotype via the PPAR-γ activation in hippocampus of CMS mice. E Experimental scheme to monitor the effect of GW9662 on PPAR-γ in Ctrl, lipopolysaccharide (LPS), LPS + ASA VI and LPS + ASA VI + GW9662 in primary microglia. F Fluorescence micrographs showing nuclear translocation of PPAR-γ in Ctrl, LPS, LPS + ASA VI and LPS + ASA VI + GW9662 microglia. PPAR-γ was stained with PPAR-γ antibody (green), Arg-1 in microglia were stained with an anti-Arg-1 antibody (red), and nuclei were stained with DAPI (blue). Scale bar, 10 μm. G Effects of GW9662 treatment on levels of p-PPAR-γ in Ctrl, LPS, LPS + ASA VI and LPS + ASA VI + GW9662 microglia (n = 3, each sample in triplicate). H Levels of mRNAs encoding the pro-inflammatory cytokines (TNF-α, iNOS, IL-1β, and IL-6) and the anti-inflammatory cytokines (Arg-1, IL-10 and TGF-β) and BDNF in Ctrl, LPS, LPS + ASA VI and LPS + ASA VI + GW9662 microglia. Data are displayed with mean ± SEM (n = 3–5), A *p < 0.05, ***p < 0.001 (two-way ANOVA with Tukey’s multiple-comparisons test). G and H *p < 0.05, *p < 0.01, ***p < 0.001 vs. Ctrl group, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. LPS group, &p < 0.05, &&&p < 0.001 vs. LPS + ASA VI group (one-way ANOVA with Tukey’s multiple-comparisons test)CC BY · PubMed Central
Fig. 5 Asperosaponin VI induces an anti-inflammatory microglial phenotype via PPAR-γ. A Timeline of the experimental process on the effect of GW9662 on ASA VI-treated CMS mice. B Effects of GW9662 treatment on levels of p-PPAR-γ, PPAR-γ-1, and PPAR-γ-2 in hippocampus of ASA VI + CMS mice (n = 3, each sample in triplicate). C and D Effects of GW9662 treatment on microglia with pro- or anti-inflammatory phenotypes in hippocampus of ASA VI + CMS mice. Scale bar, 50 μm. E Effects of GW9662 treatment on the ratio of Arg-1+ microglia to iNOS+ microglia in hippocampus of ASA VI + CMS mice. F Effects of GW9662 treatment on mRNA levels of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), anti-inflammatory cytokines (IL-10 and TGF-β) and BDNF. G Effects of GW9662 treatment on protein levels of IL-1β and IL-10 in hippocampus of ASA VI + CMS mice. Data for individual animals are displayed (mean ± SEM, n = 3–6), B–E and G *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA with Tukey’s multiple-comparisons test). F *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl group, #p < 0.05, ##p < 0.01 vs. CMS group, &p < 0.05, &&p < 0.01, &&&p < 0.001 vs. CMS + ASA VI group (one-way ANOVA with Tukey’s multiple-comparisons test)
Fig. 5 Asperosaponin VI induces an anti-inflammatory microglial phenotype via PPAR-γ. A Timeline of the experimental process on the effect of GW9662 on ASA VI-treated CMS mice. B Effects of GW9662 treatment on levels of p-PPAR-γ, PPAR-γ-1, and PPAR-γ-2 in hippocampus of ASA VI + CMS mice (n = 3, each sample in triplicate). C and D Effects of GW9662 treatment on microglia with pro- or anti-inflammatory phenotypes in hippocampus of ASA VI + CMS mice. Scale bar, 50 μm. E Effects of GW9662 treatment on the ratio of Arg-1+ microglia to iNOS+ microglia in hippocampus of ASA VI + CMS mice. F Effects of GW9662 treatment on mRNA levels of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), anti-inflammatory cytokines (IL-10 and TGF-β) and BDNF. G Effects of GW9662 treatment on protein levels of IL-1β and IL-10 in hippocampus of ASA VI + CMS mice. Data for individual animals are displayed (mean ± SEM, n = 3–6), B–E and G *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA with Tukey’s multiple-comparisons test). F *p < 0.05, **p < 0.01, ***p < 0.001 vs. Ctrl group, #p < 0.05, ##p < 0.01 vs. CMS group, &p < 0.05, &&p < 0.01, &&&p < 0.001 vs. CMS + ASA VI group (one-way ANOVA with Tukey’s multiple-comparisons test)CC BY · PubMed Central
Fig. 6 Asperosaponin VI restores the microglia–neuron crosstalk in vivo and in vitro. A and B Effects of GW9662 treatment on mRNA and protein levels of ligand-receptor pairs that mediate crosstalk between neurons and microglia (Cx3CR1/Cx3CL1, CD200/CD200R) in hippocampus of ASA VI + CMS mice. C Schematic diagram of the neuron–microglia cell co-culture system. Neurons were seeded in the top compartment of the transwell, and microglia were cultured in the bottom compartment. Subsequently, the co-cultured cells were treated with PBS or LPS for 24 h in presence or absence ASA VI or/and GW9662. D and E The effects of GW9662 treatment on endogenous CX3CR1 and CD200R expression in primary microglia by immunofluorescence staining and western blotting after the microglia co-cultured with neuron were treat with LPS for 24 h in presence ASA VI. Scale bar, 5 μm. Data are displayed with mean ± SEM (n = 4–5), *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA with Tukey’s multiple-comparisons test)
Fig. 6 Asperosaponin VI restores the microglia–neuron crosstalk in vivo and in vitro. A and B Effects of GW9662 treatment on mRNA and protein levels of ligand-receptor pairs that mediate crosstalk between neurons and microglia (Cx3CR1/Cx3CL1, CD200/CD200R) in hippocampus of ASA VI + CMS mice. C Schematic diagram of the neuron–microglia cell co-culture system. Neurons were seeded in the top compartment of the transwell, and microglia were cultured in the bottom compartment. Subsequently, the co-cultured cells were treated with PBS or LPS for 24 h in presence or absence ASA VI or/and GW9662. D and E The effects of GW9662 treatment on endogenous CX3CR1 and CD200R expression in primary microglia by immunofluorescence staining and western blotting after the microglia co-cultured with neuron were treat with LPS for 24 h in presence ASA VI. Scale bar, 5 μm. Data are displayed with mean ± SEM (n = 4–5), *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA with Tukey’s multiple-comparisons test)CC BY · PubMed Central
Fig. 7 Asperosaponin VI prevents the CMS-induced synaptic dysfunction of hippocampal neurons via a PPAR-γ-dependent pathway. A Fluorescence micrographs of mature neurons in the DG of hippocampus, identified through staining for NeuN. At right is quantification of the area of NeuN+ cells in the DG. Each dot in the bar graph represents the average of 5–6 micrographs for each mouse (n = 5). B and C Effects of asperosaponin VI on levels of PSD95, CamKII α, CamKII β, and p-GluA2 in hippocampus of CMS mice treated with GWP662 or not. Levels of proteins were normalized to those of β-actin (n = 3, each sample in triplicate). D Correlation of the levels of p-PPA-γ with the levels of PSD-95, CamKII α, CamKII β, and p-GluA2. E Effects of GW9662 treatment on the sucrose preference (SPT), immobility time in tail suspension test (TST) and forced swimming test (FST) and the traveled distance in open field test (OFT) of ASA VI + CMS mice (n = 7–9). Data for individual animals are displayed (mean ± SEM), *p < 0.05, **p < 0.01, ***p < 0.005 (one-way ANOVA with Tukey’s multiple-comparisons test)
Fig. 7 Asperosaponin VI prevents the CMS-induced synaptic dysfunction of hippocampal neurons via a PPAR-γ-dependent pathway. A Fluorescence micrographs of mature neurons in the DG of hippocampus, identified through staining for NeuN. At right is quantification of the area of NeuN+ cells in the DG. Each dot in the bar graph represents the average of 5–6 micrographs for each mouse (n = 5). B and C Effects of asperosaponin VI on levels of PSD95, CamKII α, CamKII β, and p-GluA2 in hippocampus of CMS mice treated with GWP662 or not. Levels of proteins were normalized to those of β-actin (n = 3, each sample in triplicate). D Correlation of the levels of p-PPA-γ with the levels of PSD-95, CamKII α, CamKII β, and p-GluA2. E Effects of GW9662 treatment on the sucrose preference (SPT), immobility time in tail suspension test (TST) and forced swimming test (FST) and the traveled distance in open field test (OFT) of ASA VI + CMS mice (n = 7–9). Data for individual animals are displayed (mean ± SEM), *p < 0.05, **p < 0.01, ***p < 0.005 (one-way ANOVA with Tukey’s multiple-comparisons test)CC BY · PubMed Central
Fig. 8 Mechanism by which asperosaponin VI improve CMS-induced depression. Stress induces a pro-inflammatory microglial phenotype (iNOS+-Iba1+ cells) in hippocampus, that causes reduced crosstalk between microglia and neuron, inflammation and synaptic dysfunction in the hippocampus, ultimately leading to depression-like behaviors. Asperosaponin VI may ameliorate the effects of stress by inducing microglia to adopt a PPAR-γ-dependent anti-inflammatory phenotype (Arg+-Iba1+ cells) which releasing anti-inflammatory and neuroprotective molecules
Fig. 8 Mechanism by which asperosaponin VI improve CMS-induced depression. Stress induces a pro-inflammatory microglial phenotype (iNOS+-Iba1+ cells) in hippocampus, that causes reduced crosstalk between microglia and neuron, inflammation and synaptic dysfunction in the hippocampus, ultimately leading to depression-like behaviors. Asperosaponin VI may ameliorate the effects of stress by inducing microglia to adopt a PPAR-γ-dependent anti-inflammatory phenotype (Arg+-Iba1+ cells) which releasing anti-inflammatory and neuroprotective moleculesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 89

Metadata

Authors
Jiang, X., Yi, S., Liu, Q., Su, D., Li, L., Xiao, C., & Zhang, J.
Affiliations
Guizhou University (CN)
Corresponding author
Zhang, Jinqiang
Venue
Journal of Neuroinflammation
Published
2022-05-24
Volume
19
Issue
1
Pages
115-115
ISSN
1742-2094 (ISSN-L)
OpenAlex
W4281392930
Cited by
89
References
67
Citations by year
2026: 21 · 2025: 20 · 2024: 28 · 2023: 17 · 2022: 3
FWCI
5.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81960811, 82060726)
  • PhD Start-up Fund of the Guizhou University of Traditional Chinese Medicine ([2019]31)
  • Guizhou Science and Technology Plan Project ([2019]5611)
  • Department of Science and Technology of Guizhou High-level Innovative Talents ([2018]5638-2)
  • Department of Science and Technology of Guizhou basic research ([2019]1026)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
asperosaponin VI, chronic mild stress, depression-like behavior, antidepressants, microglial phenotype, neuroprotection, PPARγ signaling, hippocampus, Arg1, inflammatory cytokines, anti-inflammatory cytokines, CX3CL1/CX3CR1, synaptic function, PSD-95, CaMKII, imipramine, natural products, neuroinflammation
MeSH terms
Animals, Antidepressive Agents, Depression, Hippocampus, Phenotype, Saponins, Stress, Psychological, Cytokines, Microglia, PPAR gamma, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Asperosaponin VI ameliorates the CMS-induced depressive-like behaviors by inducing a neuroprotective microglial phenotype in hippocampus via PPAR-γ pathway. https://app.cochat.ai/papers/10.1186/s12974-022-02478-y
The paper
Jiang, X., Yi, S., Liu, Q., Su, D., Li, L., Xiao, C., & Zhang, J. (2022). Asperosaponin VI ameliorates the CMS-induced depressive-like behaviors by inducing a neuroprotective microglial phenotype in hippocampus via PPAR-γ pathway. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-022-02478-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.